Pale yellow oval extended-release film-coated tablet
Packaging
30 tablets per bottle
Approval status
Active
MFDS item code 202501911 · Approved 2025.07.25
Summary
Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal.
Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily.
Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing. This medicine may not dissolve completely and may be excreted in the feces.
It is not known whether the material excreted in the feces contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions).
⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted.
Special populations
Renal impairment
Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment.
No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows.
- The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine.
The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately.
Older adults
In patients 75 years of age and older, consider renal function and the risk of volume depletion.
Improvement of glycemic control in adults with type 2 diabetes mellitus
Blood glucose control issues in patients with type 2 diabetes
poor blood glucose control
cardiovascular disease
View approved original textHide original text
This medication is used in combination with dietary and exercise regimens to help control blood sugar in adults with type 2 diabetes. It is particularly used in patients with cardiovascular diseases among those whose blood sugar control is inadequate. For precautions related to the occurrence of cardiovascular events, please refer to professional information. In summary, this drug is used to enhance blood glucose control in patients with type 2 diabetes.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal.
Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily.
Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing. This medicine may not dissolve completely and may be excreted in the feces.
It is not known whether the material excreted in the feces contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions).
⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted.
Special populations
Renal impairment
Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment.
No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows.
- The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine.
The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately.
Older adults
In patients 75 years of age and older, consider renal function and the risk of volume depletion.
Precautions
This medication helps control blood sugar levels. However, there are several important points to be aware of when using it.
First, this medication can rarely cause a serious condition called lactic acidosis. Lactic acidosis can build up excessive lactate in the body, becoming dangerous, so if any unusual symptoms or discomfort occur while taking this drug, consult your doctor immediately.
Second, hypoglycemia may occur when used with other diabetes medications, so caution is needed, especially when combined with insulin or sulfonylureas.
Third, patients with poor kidney function, acute kidney disease, cardiovascular diseases such as heart failure or acute myocardial infarction, and those with liver dysfunction should not use this medication.
Fourth, this medication should be temporarily discontinued before and after tests using iodine contrast agents, and should be resumed only after normal kidney function is confirmed.
Fifth, patients about to undergo surgery should stop taking this medication 48 hours before surgery and resume only after confirming normal renal function post-surgery.
Sixth, this medication may cause fluid volume loss; therefore, special caution is required when symptoms such as dehydration, diarrhea, or vomiting occur.
Seventh, women who are pregnant or may become pregnant should avoid this medication, and it should also be avoided while breastfeeding.
Eighth, elderly patients or those with impaired kidney function should consult with a doctor before taking this medication and should undergo regular kidney function tests.
Ninth, avoiding alcohol consumption during treatment with this medication is advisable, as alcohol can increase the risk of lactic acidosis.
Finally, this medication is in a swallowable tablet form and should not be crushed or chewed, but swallowed whole. Sometimes, the tablet coating may be excreted in the stool, but this is normal.
If any unusual symptoms occur while taking this medication or if there are any concerns, it is essential to consult healthcare professionals for appropriate action.
Side effects
Hypoglycemia
urinary tract infection
genital infection
increased urination
decreased and deficiency of vitamin B12
ketoacidosis
lactic acidosis
decreased fluid volume
nausea
vomiting
Show 162 moreCollapse
diarrhea
abdominal pain
loss of appetite
constipation
abnormal liver function tests
hepatitis
dysgeusia
pruritus
rash
urticaria
erythema
angioedema
dysuria
interstitial nephritis
thirst
increased serum lipids
increased serum creatinine
decreased glomerular filtration rate
increased hematocrit
perineal necrosis
chronic gastritis
various neurological disorders
cerebral infarction
soft tissue infection
pneumonia
ankle fracture
epicondylitis
facial bone fracture
musculoskeletal pain
myocardial infarction
pancreatic carcinoma
diarrhea
nausea
gastric ulcer
colitis
vomiting
ischemic colitis
colonic hemorrhage
appendiceal abscess
appendicitis
meningitis
chronic otitis media
peritonsillar abscess
pulmonary tuberculosis
sepsis
subcutaneous abscess
adnexal-ovarian abscess
vestibular neuritis
headache
positional vertigo
dizziness
drowsiness
weakness
chest discomfort
chest pain
fever
facial swelling
edema
vascular stent stenosis
vascular stent thrombosis
increased alanine aminotransferase
increased aspartate aminotransferase
weight loss
urinary stones
cervical inflammation
hyperglycemia
hyponatremia
vulvar pruritus
insomnia
nasopharyngitis
shingles
glaucoma
pathological myopia
retinal detachment
retinal vein occlusion
rhegmatogenous retinal detachment
dry eye
cough
dyspnea
unstable angina
hypertension
anxiety
acute cholecystitis
autoimmune hepatitis
cholelithiasis
otalgia
positional dizziness
vertigo
anemia
lymphadenopathy
hypothyroidism
thyroid nodule
dermoid cyst
seborrheic dermatitis
atopic dermatitis
diabetic foot
nummular eczema
heat rash
sebaceous hyperplasia
lumbar spinal stenosis
myalgia
limb pain
musculoskeletal chest pain
arthralgia
cervical stenosis
fibromyalgia
flank pain
fracture pain
muscle weakness
osteoarthritis
osteoporosis
rotator cuff syndrome
astigmatism
cataract
allergic conjunctivitis
blurred vision
corneal erosion
eye discomfort
conjunctival injection
eyelid edema
visual impairment
vitreous floaters
vitreous hemorrhage
epistaxis
asthma
exertional dyspnea
wet cough
allergic rhinitis
residual sputum
skin laceration
contusion
rib fracture
concussion
corneal abrasion
fall
hand fracture
iliotibial band syndrome
open globe injury
pelvic fracture
road traffic accident
splenic injury
sternum fracture
angina
palpitations
Prinzmetal angina
coronary artery disease
atherosclerosis
deep vein thrombosis
diabetic vascular complications
peripheral artery obstructive disease
benign neoplasm of the ampulla of Vater
benign ovarian tumor
bladder cancer
cholesteatoma
gastric cancer
leiomyoma
rectal cancer
thyroid cancer
uterine leiomyoma
anxiety
depression
sleep disorders
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly closed container to protect it from exposure to air and light. It is important to maintain storage temperatures between 1 to 30 degrees Celsius.
Appearance and packaging
Appearance
Pale yellow oval extended-release film-coated tablet
Package unit
30 tablets per bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.